NORTH CHICAGO - AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration ( FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A; ABBV-400 ...
At the University of Missouri, plant scientist Ron Mittler is rewriting the playbook for how scientists study life by asking ...
SeaStar Medical Holding Corp. ( ICU ), a commercial-stage healthcare company, said the U.S. FDA has granted Breakthrough Device Designation to its Selective Cytopheretic Device (SCD) therapy for ...
NSCLC development advances after FDA Breakthrough Therapy Designation for previously treated EGFR wild-type, c-Met disease.
Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults ...
Flat Medical, a provider of precision needle access and guidance solutions for anesthesia, critical care, and pain management, today announced that more than 30 hospitals and pain management centers ...
Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the ...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the U.S. Food and Drug Administration ...
Reinsurance Group of America upgraded to Buy after strong underwriting and investment returns. See here for a detailed ...
Curaleaf International, part of Curaleaf Holdings, Inc. (TSX:CURA) in partnership with Jupiter Research LLC, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results